Advertisement

Topics

Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies

20:00 EDT 10 Jul 2018 | NIH

Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. According to the World Health Organization, human rabies caused by the classical rabies virus continues to be almost 100% fatal once clinical symptoms of rabies appear, with no specific treatment available anywhere in the world.

CDC researchers have identified lyssavirus-specific antibodies for the treatment and prevention of rabies in humans post-exposure. They have also developed a method using a naïve antibody phage display library to identify phage clones that bind recombinant rabies virus or cells from multiple lyssaviruses. The sequence of domain antibodies specific for lyssaviruses can be used to engineer a monoclonal antibody for targeting in human rabies post-exposure prophylaxis or antiviral therapy of clinical rabies (when a patient manifests with rabies symptoms such as headache, confusion, agitation, delirium, etc.). This technology also offers the support to improve the spectrum of biological activity against non-rabies lyssaviruses.

IC: 
CDC
NIH Ref. No.: 
E-263-2013-0
Advantages: 
  • Currently, there are no specific treatments available to treat and cure clinical rabies after the onset of symptoms
  • Commercial anti-rabies immune globulins (Ig) do not neutralize other lyssaviruses, such as Lagos Bat, Mokola (MOK) and West Caucasian Bat viruses (WCBV)
Applications: 
  • Antibodies can be used directly in rabies post-exposure prophylaxis or antiviral therapy of clinical rabies
  • Method offers support to improve the spectrum of biological activity against non-rabies lyssaviruses
  • Antibody phage library can be used for additional research
Provider Technology ID: 
3307
Updated On: 
Jul 11, 2018
Provider Classifications: 
Date Published: 
Wednesday, July 11, 2018
Patent Application: 
61/394,651
PCT/US2011/056738
13/879,782
14/813,427
15/725,557
Publications: 
Patent Authority: 
US
PCT
US
US
US
Patent Number: 
9,115,187
9,809,643
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
CDC
CDC
LPM FIrst Name: 
Jeremiah
LPM Last Name: 
Mitzelfelt
LPM Address: 
BG 5601FL RM 2G29 MSC 9804 5601 FISHERS LN
LPM City: 
Bethesda
LPM Zip: 
20892-9804
Inv Is lead: 
LPM State: 
MD
LPM Phone: 
301-443-8518
LPM Organization: 
NIH Office of Technology Transfer
DTDT Classification: 
Devices/Instruments; Software; Mfg Technology/Methods; Research Tools & Material
Diagnostics
Methods
Therapeutics
Infectious Diseases
Diagnostics
Viral
Non-AIDS (only)
Therapeutics
Anti-virals
Non-AIDS (only)
Research Materials
Research Tool
Therapeutic (small molecule)
Antibody
Vaccine
Vaccine
DTDT Description: 
Devices/Instrumentation
Devices/Instrumentation - Diagnostics
Devices/Instrumentation - Diagnostics: Methods
Devices/Instrumentation - Therapeutics
Infectious Diseases
Infectious Diseases - Diagnostics
Infectious Diseases - Diagnostics - Viral
Infectious Diseases - Diagnostics - Viral: Non-AIDS
Infectious Diseases - Therapeutics
Infectious Diseases - Therapeutics - Anti-virals
Infectious Diseases - Therapeutics - Anti-virals: Non-AIDS
Infectious Diseases - Research Materials
Research Tool
Therapeutic (small molecule)
Antibody
Vaccine
Vaccine
Pat Filing Date: 
2010-10-19
2011-10-18
2013-04-16
2015-07-30
2017-10-05
Patent Issue Date: 
2015-08-25
2017-11-07
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/21601054
Publication Caption: 
PMID 21601054
Publication Title: 

Smith TG, et al.

Additional Patents: 
International patents issued in Europe and Canada
Disease Area Term: 
Technology Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize:- Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies.
For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

Related Patents: 
9,248,179
Related Patent Publish Date: 
1277355600
1308805200
1356069600
1450764000
Related Patent Application: 

61/358,288

PCT/US2011/041579

13/806,622

14/978,135

Related Patent Authority: 
US
PCT
US
US
Related Invention: 
E-256-2013-0
E Number Only: 
E-263-2013-0
Inventor First Name: 
Xianfu
Todd
Inventor Last Name: 
Wu
Smith

Original Article: Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies

NEXT ARTICLE

More From BioPortfolio on "Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...